FDA Clearance Tracker · DEN190056
ADVIA Centaur Enhanced Liver Fibrosis (ELF)
Last checked: Nov 19, 2026Latest source record: Aug 20, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Aug 20, 2021
De Novo granted
Time to decision
603 days
Received Dec 26, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN190056
- Device name
- ADVIA Centaur Enhanced Liver Fibrosis (ELF)
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Applicant location
- Tarrytown, NY
- Received
- Dec 26, 2019
- Decided
- Aug 20, 2021
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device class
- Class II
- Regulation
- 21 CFR 862.1622
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for DEN190056
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Siemens Healthcare Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260674 · Decided Nov 6, 2026 · 249 days after receipt
Device type: System, Test, Vitamin D (MRG) · Laboratory Medicine & Pathology
- Atellica IM CA 19-9 II510(k)
K253528 · Decided Aug 10, 2026 · 270 days after receipt
Device type: System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer (NIG) · Laboratory Medicine & Pathology
K261364 · Decided Jul 24, 2026 · 88 days after receipt
Device type: Colorimetry, Acetaminophen (LDP) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.